Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients

Oleg Blyuss, Alexey Zaikin, Valeriia Cherepanova, Daniel Munblit, Elena M Kiseleva, Olga M Prytomanova, Stephen W Duffy, Tatjana Crnogorac-Jurcevic

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
22 Downloads (Pure)

Abstract

BACKGROUND: An accurate and simple risk prediction model that would facilitate earlier detection of pancreatic adenocarcinoma (PDAC) is not available at present. In this study, we compare different algorithms of risk prediction in order to select the best one for constructing a biomarker-based risk score, PancRISK.
METHODS: Three hundred and seventy-nine patients with available measurements of three urine biomarkers, (LYVE1, REG1B and TFF1) using retrospectively collected samples, as well as creatinine and age, were randomly split into training and validation sets, following stratification into cases (PDAC) and controls (healthy patients). Several machine learning algorithms were used, and their performance characteristics were compared. The latter included AUC (area under ROC curve) and sensitivity at clinically relevant specificity.
RESULTS: None of the algorithms significantly outperformed all others. A logistic regression model, the easiest to interpret, was incorporated into a PancRISK score and subsequently evaluated on the whole data set. The PancRISK performance could be even further improved when CA19-9, commonly used PDAC biomarker, is added to the model.
CONCLUSION: PancRISK score enables easy interpretation of the biomarker panel data and is currently being tested to confirm that it can be used for stratification of patients at risk of developing pancreatic cancer completely non-invasively, using urine samples.
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalBritish Journal of Cancer (BJC)
DOIs
Publication statusPublished - 20 Dec 2019

Fingerprint

Dive into the research topics of 'Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients'. Together they form a unique fingerprint.

Cite this